Abstract
Breast cancer has an increasing incidence worldwide and therefore attention was focused on optimizing the therapeutic strategies in such cases; in both breast and axillary management a trend to de-escalation of the surgical treatment has been reported. This fact being possible especially due to the wide use of high technology systems such as angiography and near infrared imaging. Meanwhile, the wide usage of indocyanine green lead to better oncologic and cosmetic outcomes and lower rates of short term and long-term complications. The aim of this paper is to analyse the cost efficiency of indocyanine green and near infrared light in breast cancer patients.